The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Clinical evidence supporting rituximab
Won Seog Kim, MD, PhD from Sungkyunkwan University, Seoul, South Korea discusses his presentation on the biosimilar rituximab, given during the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Prof. Kim describes the process of biosimilar production and how this differs from the manufacturing of originator biologics. Providing an overview of the data he presented, Prof. Kim speaks about the efficacy of rituximab in the treatment of chronic lymphocytic leukemia and the supporting clinical evidence. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
